Informatics confronts drug–drug interactions
Drug–drug interactions (DDIs) are an emerging threat to public health. Recent estimates
indicate that DDIs cause nearly 74000 emergency room visits and 195000 hospitalizations …
indicate that DDIs cause nearly 74000 emergency room visits and 195000 hospitalizations …
Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450
T Niwa, Y Imagawa, H Yamazaki - Current drug metabolism, 2014 - ingentaconnect.com
This article reviews in vitro metabolic and in vivo pharmacokinetic drug–drug interactions of
nine antifungal agents: six azoles (fluconazole, itraconazole, ketoconazole, miconazole …
nine antifungal agents: six azoles (fluconazole, itraconazole, ketoconazole, miconazole …
Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of …
OA Fahmi, S Hurst, D Plowchalk, J Cook, F Guo… - Drug Metabolism and …, 2009 - ASPET
Cytochrome P450 3A4 (CYP3A4) is the most important enzyme in drug metabolism and
because it is the most frequent target for pharmacokinetic drug-drug interactions (DDIs) it is …
because it is the most frequent target for pharmacokinetic drug-drug interactions (DDIs) it is …
Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance
HS Brown, M Griffin, JB Houston - Drug metabolism and disposition, 2007 - ASPET
Human liver microsomes have typically resulted in marked underprediction of in vivo human
intrinsic clearance (CLint); therefore, the utility of cryopreserved hepatocytes as an …
intrinsic clearance (CLint); therefore, the utility of cryopreserved hepatocytes as an …
Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions
EJ Guest, L Aarons, JB Houston… - Drug metabolism and …, 2011 - ASPET
Current assessment of drug-drug interaction (DDI) prediction success is based on whether
predictions fall within a two-fold range of the observed data. This strategy results in a …
predictions fall within a two-fold range of the observed data. This strategy results in a …
Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant
G Chen, R Lee, AM Højer, JK Buchbjerg… - Clinical drug …, 2013 - Springer
Abstract Background and Objective The identification and quantification of potential drug–
drug interactions is important for avoiding or minimizing the interaction-induced adverse …
drug interactions is important for avoiding or minimizing the interaction-induced adverse …
In vitro and in vivo methods to assess pharmacokinetic drug– drug interactions in drug discovery and development
C Lu, L Di - Biopharmaceutics & drug disposition, 2020 - Wiley Online Library
Drug–drug interactions (DDIs) caused by the co‐administration of multiple drugs are major
safety concerns in the clinic. Several drugs have been withdrawn from the market due to …
safety concerns in the clinic. Several drugs have been withdrawn from the market due to …
General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs
Y Ohno, A Hisaka, H Suzuki - Clinical pharmacokinetics, 2007 - Springer
Abstract Background Cytochrome P450 (CYP) 3A4 is the most prevalent metabolising
enzyme in the human liver and is also a target for various drug interactions of significant …
enzyme in the human liver and is also a target for various drug interactions of significant …
Methods for predicting in vivo pharmacokinetics using data from in vitro assays
JB Houston, A Galetin - Current drug metabolism, 2008 - ingentaconnect.com
Strategies for optimising in vivo predictions from in vitro data on metabolic stability and CYP
inhibition are discussed. Potential pitfalls and areas of inaccuracy are highlighted together …
inhibition are discussed. Potential pitfalls and areas of inaccuracy are highlighted together …
Evaluation of a new molecular entity as a victim of metabolic drug-drug interactions—an industry perspective
T Bohnert, A Patel, I Templeton, Y Chen, C Lu… - Drug Metabolism and …, 2016 - ASPET
Under the guidance of the International Consortium for Innovation and Quality in
Pharmaceutical Development (IQ), scientists from 20 pharmaceutical companies formed a …
Pharmaceutical Development (IQ), scientists from 20 pharmaceutical companies formed a …